ReviewBiogerontology2025
Enhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits.
Review in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Safety of 8-Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Study.Phytotherapy research : PTR · 2026Trial
- Ashwagandha Root Extract Stabilises Physiological Stress Responses in Male and Female Team Sports Athletes During Pre-Season Training.Nutrients · 2026Trial
- Efficacy and safety of a sustained release ashwagandha root extract capsules on muscle strength and cardiorespiratory endurance in recreationally active individuals: a randomized, double-blind, placebo-controlled trial.Frontiers in nutrition · 2026Trial
- Nutraceutical Applications ofFoods (Basel, Switzerland) · 2026Review
- New Vistas for Withania somnifera in Signal Transduction of Inflammation and Aging.Pharmaceutical research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ashwagandha (Withania somnifera), a revered herb in Ayurvedic medicine, has gained significant scientific recognition for its potential to promote healthy aging. Traditionally used as a Rasayana or rejuvenator, this potent adaptogen helps the body manage stress and enhance vitality. This review synthesises extensive evidence for its multifaceted anti-aging capabilities, which target key hallmarks of the aging process. The mechanisms underpinning its effects include enhancing telomerase activity to support cellular longevity, combating systemic oxidative stress, and powerfully countering inflammaging by modulating immune responses and lowering inflammatory markers like C-reactive protein. Robust clinical evidence demonstrates its efficacy in improving crucial physiological parameters, including significant gains in muscle strength and size, enhanced cardiorespiratory fitness, hormonal balance, skin health, and improved sleep quality in older adults. Furthermore, trials have consistently shown its ability to improve cognitive function, including memory and information-processing speed, particularly in adults with mild cognitive impairment. Promising preclinical data also highlight its neuroprotective potential in models of Alzheimer's and Parkinson's disease. Here, we review the current evidence supports Ashwagandha's therapeutic potential in extending healthspan and enhancing quality of life. Large-scale, long-term clinical trials using standardized extracts are essential to fully confirm its role in healthy aging within the global population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.